Header Logo

Connection

KAZUHARU KAI to Rituximab

Back to Details
This is a "connection" page, showing publications KAZUHARU KAI has written about Rituximab.
KAZUHARU KAI
Connection Strength
0.131
Rituximab
  1. Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. Future Oncol. 2021 Sep; 17(27):3549-3560.
    View in: PubMed
    Score: 0.131
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.